Xilio Therapeutics, Inc. (XLO)
NASDAQ: XLO · Real-Time Price · USD
8.33
-0.26 (-3.03%)
Apr 15, 2026, 3:40 PM EDT - Market open

Xilio Therapeutics Ratios and Metrics

Millions USD. Fiscal year is Jan - Dec.
Fiscal Year
CurrentFY 2025FY 2024FY 2023FY 2022FY 2021
Period Ending
Apr '26 Dec '25 Dec '24 Dec '23 Dec '22 Dec '21
4841441574438
Market Cap Growth
24.71%-7.07%187.78%-79.42%-83.15%-
Enterprise Value
-80.91-91.31-4.64-21.38-34.26259.42
Last Close Price
8.338.9613.377.7037.66224.00
PE Ratio
--2.14-0.88-0.20-0.84-1.18
PS Ratio
1.130.936.89---
PB Ratio
1.101.152.480.410.702.36
P/TBV Ratio
2.092.122.900.410.700.48
P/FCF Ratio
--7.37-2.37-0.22-0.95-5.35
P/OCF Ratio
--8.13-2.38-0.22-0.97-5.42
EV/Sales Ratio
--2.09-0.73---
EV/EBITDA Ratio
-2.260.080.280.39-3.53
EV/EBIT Ratio
-2.180.080.270.38-3.46
EV/FCF Ratio
-16.570.250.310.44-3.17
Debt / Equity Ratio
0.160.160.400.220.120.11
Debt / EBITDA Ratio
-0.16-0.17-0.14-0.16-0.23-0.28
Debt / FCF Ratio
-1.26-1.26-0.44-0.18-0.26-0.25
Net Debt / Equity Ratio
-3.70-3.70-2.68-0.87-0.95-0.96
Net Debt / EBITDA Ratio
3.013.230.800.421.152.41
Net Debt / FCF Ratio
23.7023.702.560.471.302.17
Asset Turnover
0.390.390.10000
Quick Ratio
2.442.442.032.805.7015.50
Current Ratio
2.582.582.213.025.8915.85
Return on Equity (ROE)
-143.61%-132.53%-214.02%-107.25%-60.62%-84.15%
Return on Assets (ROA)
-39.79%-37.19%-91.79%-79.10%-49.91%-59.00%
Return on Invested Capital (ROIC)
-1640.28%-1533.31%-1532.95%-1582.19%-1326.62%-2495.23%
Return on Capital Employed (ROCE)
-63.15%-59.04%-136.47%-97.09%-55.14%-68.39%
Earnings Yield
-70.54%-46.75%-113.99%-505.45%-119.70%-84.50%
FCF Yield
-11.09%-13.57%-42.14%-455.12%-105.17%-18.70%
Buyback Yield / Dilution
-18.53%-118.70%-94.61%-0.38%-388.59%-970.34%
Total Shareholder Return
-18.53%-118.70%-94.61%-0.38%-388.59%-970.34%
Updated Mar 23, 2026. Data Source: Fiscal.ai. Standard template. Financial Sources.
SEC Filings: 10-K · 10-Q